Sands looks to restart Macau casino work next year

Sands looks to restart M

November 16, 2009 02:02
2 minute read.


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


US casino operator Las Vegas Sands Corp. plans to resume work in January on its multibillion-dollar gambling resorts in Macau after suspending construction last year amid a massive funding crunch, the company said Sunday. This week Sands will seek to raise more than $3.3 billion from an initial public offering of shares in its casino businesses in the southern Chinese enclave, the world's largest casino market. About $500 million will be used to restart construction on the projects, executives said. The company plans to hire as many as 12,000 workers after 11,000 jobs were cut as a result of the suspension. The projects, including casinos and Shangri-La and Sheraton hotels, were stalled last year as the company grappled with a cash shortage, brought on by the financial crisis and Sands' massive debt load, that threatened its agreements with creditors. Sands' latest casino resorts are part of Chairman Sheldon Adelson's quest to turn a section of Macau known as the Cotai Strip into a Chinese version of the Las Vegas Strip with a mix of gambling, conventions, shopping, entertainment and other draws. "We expect that Macau will evolve into the same type of business model that the integrated resorts on the Las Vegas Strip have evolved into," Adelson said in a video conference with reporters in Hong Kong. Sands hopes to open the first phase of the project, including two hotel towers and casino space at a cost of $2 billion, by June 2011. Ultimately, the company aspires to build still more casinos and hotels on two additional plots of land in the Cotai area to bring the total number of hotel rooms to 20,000. Adelson repeated his goal of luring a wider variety of visitors to Macau, which relies overwhelmingly on day-trippers and high-stakes gamblers for profits, whereas Las Vegas earns a larger portion from non-gambling activities like shows and shopping. Despite its attempts to diversify, Sands' Macau business is still heavily dependent on gambling. The company - which currently runs two resorts, the Sands Macao and the popular Venetian - derives some 80 percent of its revenues from VIP and mass-market gambling, the company said. Its Macau profits before interest, tax and other adjustments were forecast to rise from $686 million in 2008 to $803 million this year, as the city's gambling industry rebounds sharply with the help of a stronger Chinese economy. Sands' new shares are expected to begin trading on the Hong Kong Stock Exchange on Nov. 30, with the share price to be determined Nov. 21, according to the IPO's terms. It will mark the second Hong Kong IPO from an American casino operator. Shares in the Macau resorts of billionaire Steve Wynn debuted last month after a $1.63 billion IPO.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection